Page 10 - Pharmaceutical

Suresh Subramanian to head Biocon's branded formulations business in India

He has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline, Novartis, AstraZeneca and Pfizer

Zydus partners with Japan's Takeda to develop vaccine for chikungunya

Early stage project will develop a vaccine for chikungunya, for which there is currently no vaccine or medicine to treat it

Glenmark inks pact with Lubrizol arm Particle Sciences to develop generic cancer drug

As per the deal, Glenmark will have global exclusive marketing rights of the product - a generic version of cancer drug Abraxane that had worldwide sales of $ 967 million in 2015

Themis Medicare joins hand with Nevakar to tap US pharma market

As per the deal, Themis will develop a selected number of injectable products that will be manufactured and commercialised by Nevakar in the US and select global markets

Horizon Pharma buys Raptor Pharmaceutical for $ 800 million

The deal will strengthen Irish firm's focus on rare diseases and expand its operations in Europe and other international markets

Thermo Fisher opens clinical services facility in South Korea

Over the past few years, clinical trials have consistently grown in South Korea, making it a leading emerging nation for clinical trial research in Asia

Asahi Glass buys German biopharmaceutical CMO Biomeva

With this acquisition, AGC's life science business will be able to expand its geographic coverage and offer a wider range of capacities

Aralez acquires US and Canadian rights to Zontivity from Merck

Zontivity is the first and only approved therapy shown to inhibit the protease-activated receptor-1, the primary receptor for thrombin, which is considered to be the most potent activator of platelets

Glenmark receives US FDA approval for skin ointment lidocaine

The approved product is the generic version of AstraZeneca's Xylocaine ointment (5%), which recorded annual sales of approximately $ 373 million

Skin care specialist Kaya Ltd acquires 75% stake in two UAE firms

The company has acquired 75 percent stake in Minal Medical Centre, Dubai, and Minal Specialized Clinic Dermatology, Sharjah

Syngene opens R&D centre for Amgen in Bangalore

This will be Syngene's fourth such exclusive R&D centre. It already operates dedicated R&D centres for Bristol-Myers Squibb, Abbott Nutrition and Baxter Inc

Glenmark discovers new biologic drug for cancer treatment

The company is likely to file an investigational new drug (IND) application with the US FDA for the new drug, GBR 1372, in the second half of the next financial year FY 2018

Lupin receives US FDA tentative approval for antibacterial drug moxifloxacin

The approved product, moxifloxacin hydrochloride tablet, is a generic version of Bayer Healthcare's Avelox tablet

Dr Reddy's launches antidepressant drug bupropion in US

Bupropion HCl extended-release tablet (SR) is a generic version of GSK's Wellbutrin SR tablet, which is a medication primarily used as an antidepressant and smoking cessation aid

Natco's partner Mylan invalidates third Teva Copaxone patent in US

Earlier, on August 24, 2016, the US patent office invalidated two of the patents of Teva protecting Copaxone (glatiramer acetate) 40 mg dosage injection

Cadila Healthcare receives US FDA's EIR report for facility in Ahmedabad SEZ

The company has received an establishment inspection report (EIR) from the US drug regulator for its oral solid dosage drug manufacturing plant

Lupin gets US FDA nod for antibacterial drug azithromycin suspension

The approved product - azithromycin for oral suspension, 300 mg (100 mg/5 mL) and 1200 mg (200 mg/5 mL) - is the generic version of Pfizer Inc's Zithromax oral suspension

Bioelectronics open up another leg of medical therapy: Dr Mosongo Moukwa

The success of bioelectronic medicine will require the confluence of deep disease biology expertise and new highly miniaturised technologies

Pfizer buys AstraZeneca's small molecule antibiotics business for $ 725 mn

With this agreement, AstraZeneca reinforces its focus on developing novel medicines in three main therapy areas - respiratory & autoimmunity, cardiovascular & metabolic diseases, and oncology

Bal Pharma appoints Akash Mathur as CEO

Mathur has vast pharma experience in the US & Canada including a start-up and advisory role to several small and medium companies followed by 10 years of working leading pharma companies